Currently, a number of approaches that are capable of improving insulin sensitivity and adipose tissue functions, i.e., weight loss, metformin treatment, and insulin sensitization by thiazolidinediones (TZDs), have been considered for managing NAFLD [1], [13]–[15]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.